301 Association of response with survival outcomes with atezolizumab in combination with vemurafenib and cobimetinib in the phase 3 IMspire150 study

301 Association of response with survival outcomes with atezolizumab in combination with vemurafenib and cobimetinib in the phase 3 IMspire150 study

Bibliographic Details
Main Authors: Ralf Gutzmer, Caroline Robert, Thomas Eigentler, Qian Zhu, Helen Gogas, Grant McArthur, Paolo Ascierto, Daniil Stroyakovskiy, Svetlana Protsenko, Rodrigo Pereira, Lev Demidov, Georgy Moiseevich Manikhas, Haocheng Li, Edward McKenna, Virginia McNally
Format: Article
Language:English
Published: BMJ Publishing Group 2020-11-01
Series:Journal for ImmunoTherapy of Cancer
id doaj-e85259d827c149f2a0ae7f4ca214a744
record_format Article
spelling doaj-e85259d827c149f2a0ae7f4ca214a7442020-12-11T10:01:19ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262020-11-018Suppl 310.1136/jitc-2020-SITC2020.0301301 Association of response with survival outcomes with atezolizumab in combination with vemurafenib and cobimetinib in the phase 3 IMspire150 studyRalf Gutzmer0Caroline Robert1Thomas Eigentler2Qian Zhu3Helen Gogas4Grant McArthur5Paolo Ascierto6Daniil Stroyakovskiy7Svetlana Protsenko8Rodrigo Pereira9Lev Demidov10Georgy Moiseevich Manikhas11Haocheng Li12Edward McKenna13Virginia McNally1417 Department of Dermatology and Allergy, Skin Cancer Center Hannover, Hannover Medical School, Hannover, Germany 4 Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France Aff1 0000 0001 0196 8249grid.411544.1Center for Dermatooncology, Department of DermatologyUniversity Hospital Tuebingen Liebermeisterstr. 25 72076 Tuebingen Germany Department of Obstetrics and Gynecology, International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, ChinaAff1 0000 0001 2155 0800grid.5216.0First Department of Medicine, Laiko General HospitalNational and Kapodistrian University of Athens School of Medicine 11527 Athens Greece Aff2 grid.1055.10000000403978434Peter MacCallum Cancer Centre East Melbourne Australia 6Istituto Nazionale Tumori IRCCS ‘Fondazione G. Pascale’, Naples, Italy4Moscow City Oncology Hospital #62, Istra, Russian Federation6N. N. Petrov Nat’l Medical Research Ctr of Oncology, St. Petersburg, Russian Federation7Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil10N. N. Blokhin Russian Cancer Research, Moscow, Russian Federation11St. Petersburg Oncology Hospital, St. Petersburg, Russian Federation12F. Hoffmann–La Roche Ltd, Mississauga, Canada13Genentech, Inc., South San Francisco, CA, USA14Roche Products Ltd., Welwyn Garden City, UK
collection DOAJ
language English
format Article
sources DOAJ
author Ralf Gutzmer
Caroline Robert
Thomas Eigentler
Qian Zhu
Helen Gogas
Grant McArthur
Paolo Ascierto
Daniil Stroyakovskiy
Svetlana Protsenko
Rodrigo Pereira
Lev Demidov
Georgy Moiseevich Manikhas
Haocheng Li
Edward McKenna
Virginia McNally
spellingShingle Ralf Gutzmer
Caroline Robert
Thomas Eigentler
Qian Zhu
Helen Gogas
Grant McArthur
Paolo Ascierto
Daniil Stroyakovskiy
Svetlana Protsenko
Rodrigo Pereira
Lev Demidov
Georgy Moiseevich Manikhas
Haocheng Li
Edward McKenna
Virginia McNally
301 Association of response with survival outcomes with atezolizumab in combination with vemurafenib and cobimetinib in the phase 3 IMspire150 study
Journal for ImmunoTherapy of Cancer
author_facet Ralf Gutzmer
Caroline Robert
Thomas Eigentler
Qian Zhu
Helen Gogas
Grant McArthur
Paolo Ascierto
Daniil Stroyakovskiy
Svetlana Protsenko
Rodrigo Pereira
Lev Demidov
Georgy Moiseevich Manikhas
Haocheng Li
Edward McKenna
Virginia McNally
author_sort Ralf Gutzmer
title 301 Association of response with survival outcomes with atezolizumab in combination with vemurafenib and cobimetinib in the phase 3 IMspire150 study
title_short 301 Association of response with survival outcomes with atezolizumab in combination with vemurafenib and cobimetinib in the phase 3 IMspire150 study
title_full 301 Association of response with survival outcomes with atezolizumab in combination with vemurafenib and cobimetinib in the phase 3 IMspire150 study
title_fullStr 301 Association of response with survival outcomes with atezolizumab in combination with vemurafenib and cobimetinib in the phase 3 IMspire150 study
title_full_unstemmed 301 Association of response with survival outcomes with atezolizumab in combination with vemurafenib and cobimetinib in the phase 3 IMspire150 study
title_sort 301 association of response with survival outcomes with atezolizumab in combination with vemurafenib and cobimetinib in the phase 3 imspire150 study
publisher BMJ Publishing Group
series Journal for ImmunoTherapy of Cancer
issn 2051-1426
publishDate 2020-11-01
work_keys_str_mv AT ralfgutzmer 301associationofresponsewithsurvivaloutcomeswithatezolizumabincombinationwithvemurafenibandcobimetinibinthephase3imspire150study
AT carolinerobert 301associationofresponsewithsurvivaloutcomeswithatezolizumabincombinationwithvemurafenibandcobimetinibinthephase3imspire150study
AT thomaseigentler 301associationofresponsewithsurvivaloutcomeswithatezolizumabincombinationwithvemurafenibandcobimetinibinthephase3imspire150study
AT qianzhu 301associationofresponsewithsurvivaloutcomeswithatezolizumabincombinationwithvemurafenibandcobimetinibinthephase3imspire150study
AT helengogas 301associationofresponsewithsurvivaloutcomeswithatezolizumabincombinationwithvemurafenibandcobimetinibinthephase3imspire150study
AT grantmcarthur 301associationofresponsewithsurvivaloutcomeswithatezolizumabincombinationwithvemurafenibandcobimetinibinthephase3imspire150study
AT paoloascierto 301associationofresponsewithsurvivaloutcomeswithatezolizumabincombinationwithvemurafenibandcobimetinibinthephase3imspire150study
AT daniilstroyakovskiy 301associationofresponsewithsurvivaloutcomeswithatezolizumabincombinationwithvemurafenibandcobimetinibinthephase3imspire150study
AT svetlanaprotsenko 301associationofresponsewithsurvivaloutcomeswithatezolizumabincombinationwithvemurafenibandcobimetinibinthephase3imspire150study
AT rodrigopereira 301associationofresponsewithsurvivaloutcomeswithatezolizumabincombinationwithvemurafenibandcobimetinibinthephase3imspire150study
AT levdemidov 301associationofresponsewithsurvivaloutcomeswithatezolizumabincombinationwithvemurafenibandcobimetinibinthephase3imspire150study
AT georgymoiseevichmanikhas 301associationofresponsewithsurvivaloutcomeswithatezolizumabincombinationwithvemurafenibandcobimetinibinthephase3imspire150study
AT haochengli 301associationofresponsewithsurvivaloutcomeswithatezolizumabincombinationwithvemurafenibandcobimetinibinthephase3imspire150study
AT edwardmckenna 301associationofresponsewithsurvivaloutcomeswithatezolizumabincombinationwithvemurafenibandcobimetinibinthephase3imspire150study
AT virginiamcnally 301associationofresponsewithsurvivaloutcomeswithatezolizumabincombinationwithvemurafenibandcobimetinibinthephase3imspire150study
_version_ 1724386732882788352

Similar Items